<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800592</url>
  </required_header>
  <id_info>
    <org_study_id>A1481262</org_study_id>
    <nct_id>NCT00800592</nct_id>
  </id_info>
  <brief_title>Sildenafil IV Bolus Study</brief_title>
  <official_title>An Open Single Dose Study To Assess The Safety, Tolerability And Pharmacokinetics Of An Intravenous Bolus Dose (10 Mg) Of Sildenafil In Patients With Pulmonary Arterial Hypertension (PAH).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer's Upjohn has merged with Mylan to form Viatris Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety, tolerability and pharmacokinetics of&#xD;
      intravenous sildenafil (10 mg) administered as a bolus injection to patients with Pulmonary&#xD;
      Arterial Hypertension already receiving and stable on oral Revatio 20 mg TID.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic concentrations of plasma sildenafil and its metabolite</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood pressure and pulse rate from baseline (sitting and postural)</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>10 mg sildenafil bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg sildenafil bolus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>10 mg sildenafil bolus</description>
    <arm_group_label>10 mg sildenafil bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects (â‰¥18 years old) receiving oral Revatio 20 mg TID for PAH within the approved&#xD;
             indication (EU Summary of Product Characteristics) for a minimum of 1-month and who,&#xD;
             in the investigator's opinion, have demonstrated good tolerability. Subjects with PAH&#xD;
             who are nil by mouth for any reason (eg, elective surgery or medical procedure, TPN&#xD;
             feeding, gastrointestinal disturbance etc) may also be included in the study provided&#xD;
             they are haemodynamically stable (see Inclusion Criterion 4) and the 6 hour period of&#xD;
             blood pressure and pulse monitoring in the study does not interfere with any planned&#xD;
             medical or surgical intervention.&#xD;
&#xD;
          -  Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the subject has been informed of all pertinent aspects of the study.&#xD;
&#xD;
          -  Subjects who are willing and able to comply with scheduled visits, treatment plan and&#xD;
             study tests and procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any subject receiving Revatio outside ('off-label') of the current Summary of Product&#xD;
             Characteristics (SmPC).&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition that may increase the&#xD;
             risk associated with study participation or investigational product administration or&#xD;
             may interfere with the interpretation of study results and, in the judgment of the&#xD;
             investigator, would make the subject inappropriate for entry into this study.&#xD;
&#xD;
          -  Introduction of potent CYP 3A4 inhibitors (eg, ketoconazole, itraconazole and&#xD;
             ritonavir) within the previous 1 month of screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481262&amp;StudyName=Sildenafil%20IV%20bolus%20study%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 19, 2008</study_first_submitted>
  <study_first_submitted_qc>December 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2008</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sildenafil, Revatio, PAH, IV, Bolus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

